IOVA Q4 2020 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$69M

Net Income

-$68M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$86M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$768M

Total Liabilities

$112M

Stockholders' Equity

$656M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$69M	-$65M	-5.3%
Net Income	-$68M	-$64M	-7.6%